|Bid||107.78 x 100|
|Ask||107.89 x 100|
|Day's Range||102.10 - 111.85|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||54.71|
|Earnings Date||Apr 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||158.60|
Alexion slid to a 10-month low Friday after reports emerged that Brazil's government will allow drugmakers to produce biologic copies of Alexion's blockbuster drug Soliris.
Recent media reports have incorrectly stated that the Brazilian Superior Court of Justice has granted a compulsory license of Soliris® (eculizumab). Alexion would like to clarify that no compulsory license of Soliris® was requested or granted in Brazil.
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is almost flat for the week after adding about 5 percent in the week ended April 13. Will the following catalytic events lead to a resumption ...
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Alexion Pharmaceuticals (ALXN) is one of the leading biotechnology firms. Soliris is approved to treat aHUS (atypical hemolytic uremic syndrome) and PHN (paroxysmal nocturnal hemoglobinuria). Alexion’s latest acquisition of Wilson Therapeutics is a turnaround strategy that’s being implemented to restructure Alexion’s performance and investors’ sentiments in the market.
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics, which is developing a “first-of-its-kind” treatment for Wilson disease. Currently, Wilson disease is treated with copper chelators, Penicillamine or Trientine, to remove copper from serum. The drug has the potential to become the standard of care for Wilson disease patients.
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics. Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.
Wilson Therapeutics is a biopharmaceutical company focused on developing rare disease therapies. The company is listed on the Nasdaq Stockholm Exchange and has a market capitalization of 6.5 billion Swedish kronor. Wilson Therapeutics is developing a novel therapy to treat Wilson disease, which is a rare genetic and chronic disorder characterized by an accumulation of copper in the brain, liver, and other vital organs.
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.
Stock Monitor: Argos Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on Alexion Pharma, Inc. (NASDAQ: ALXN ...
Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.
Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the first quarter ended March 31, 2018 on Thursday, April 26, 2018 before the US financial markets open.
Alexion Pharmaceuticals will snap up Wilson Therapeutics in a move that helps it diversify from its blockbuster franchise and compete with Valeant and Teva.
Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.
Shares of Vertex Pharmaceuticals (VRTX) have easily outrun the market year-to-date, rising 8%, and the drug maker has notched returns of more than 42% in the past year. Analyst Hartaj Singh reiterated an Outperform rating and $190 price target on the shares Wednesday, but notes that Vertex could see as much as 50% upside to that target, which would put the shares at $285.
Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues. Alexion was one of the stars of the biotech sector in the first half of this decade, but it has stumbled more recently following an exodus of top management and a sales practices scandal related to Soliris, its pricey rare disease treatment.
Alexion Pharmaceuticals Inc (NASDAQ:ALXN) generated a below-average return on equity of 4.98% in the past 12 months, while its industry returned 17.87%. An investor may attribute an inferior ROE toRead More...
Alexion Pharmaceuticals said on Wednesday it had agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns to boost its line-up of rare disease drugs. The U.S. group is acquiring the business ...
Alexion Pharmaceuticals has made a $788 million bid for Swedish biopharmaceutical company Wilson Therapeutics as it looks to bolster its portfolio of treatments for rare disorders.
Alexion Pharmaceuticals, Inc. and Wilson Therapeutics AB announced today that Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary.
When it comes to biotech stocks, a pipeline can make or break a company. Due to the nature of the clinical trial system, a company can work for years on a new drug only to have all that work disappear when a therapy is found unsafe and ineffective. After a given amount of time, any company can produce a generic version of the drug a biotech company spent millions developing and have come to depend on revenue-wise.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Over the last one-month, outflows of investor capital in ETFs holding ALXN totaled $14.43 billion.
Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.